Indication intelligence, analysis and sector perception

Cellectis (CLLS) funds MabQuest research collaboration and license agreement

March 17, 2016 9:41am

To develop a new class of monoclonal antibodies targeting PD-1

Pact includes collaboration phase funded by CLLS with both companies will pursue preclinical research on several candidates, then clinical development and commercialization phase of the best selected antibodies, led by CLLS.

The Bottom Line: MabQuest granted an exclusive option to Cellectis, allowing CLLS to get worldwide exclusive rights over the family of PD-1 antagonist antibodies. Financial terms weren’t disclosed.

CLLS opened DOWN -$0.03 to $25.22

MabQuest SA is a recently established biotech company focused on developing immune-based interventions aimed at the manipulation and modulation of the immune system. The company discovery program is to develop novel antibody candidates targeting single and/or multiple immunoregulatory mechanisms through immune engineering. The ultimate goal of the company is to develop new immunotherapies in the fields of cancer, infectious diseases and immunesenecence.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

5 hours 23 min ago
RegMed Investors (RMi) Closing Bell: I told you so

14 hours 11 min ago
RegMed Investors’ (RMi) pre-open: It’s “make” a buck day!

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.